Saskia de Groot

Saskia de Groot

Auto-generated profile, based on publicly available information

Saskia de Groot

Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2020 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
BGBogdan Grigore
Bogdan Grigore
OCORIANA CIANI
ORIANA CIANI
FDFlorian Dams
Florian Dams
CFCarlo Baldassarre Federici
Carlo Baldassarre Federici
SGSaskia de Groot
Saskia de Groot
RTRod S. Taylor
Rod S. Taylor
In the drive towards faster patient access to treatments, health technology assessment (HTA) agencies are increasingly faced with reliance on evidence from surrogate endpoints, leading to increased decision uncertainty. This study undertook an updated survey of methodological guidance for using surrogate endpoints across international HTA agencies. We reviewed HTA and economic evaluation methods guidance from European, Australian and Canadian HTA agencies. We considered how guidelines addressed the methods for handling surrogate endpoints, including (1) level of evidence, (2) methods of validation, and (3) thresholds of acceptability. Across the 73 HTA agencies surveyed, 29 (40%) had methodological guidelines that made specific reference to consideration of surrogate outcomes. Of the 45 methods documents analysed, the majority [27 (60%)] were non-technology specific, 15 (33%) focused on pharmaceuticals and three (7%) on medical devices. The principles of the European network for Health Technology Assessment (EUnetHTA) guidelines published in 2015 on the handling of surrogate endpoints appear to have been adopted by many European HTA agencies, i.e. preference for final patient-relevant outcomes and reliance on surrogate endpoints with biological plausibility and epidemiological evidence of the association between the surrogate and final endpoint. Only a small number of HTA agencies (UK National Institute for Care and Excellence; the German Institute for Medical Documentation and Information and Institute for Quality and Efficiency in Health Care; the Australian Pharmaceutical Benefits Advisory Committee; and the Canadian Agency for Drugs and Technologies in Health) have developed more detailed prescriptive criteria for the acceptance of surrogate endpoints, e.g. meta-analyses of randomised controlled trials showing strong association between the treatment effect on the surrogate and final outcomes. As the decision uncertainty associated with reliance on surrogate endpoints carries a risk to patients and society, there is a need for HTA agencies to develop more detailed methodological guidance for consistent selection and evaluation of health technologies that lack definitive final patient-relevant outcome evidence at the time of the assessment.

15 September 2017 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
SGS. de Groot
S. de Groot
WRW. K. Redekop
W. K. Redekop
MVM. M. Versteegh
M. M. Versteegh
SSS. Sleijfer
S. Sleijfer
EOE. Oosterwijk
E. Oosterwijk
CGC. A. Uyl-De Groot
C. A. Uyl-De Groot
Purpose Based on improvements of progression-free survival (PFS), new agents for metastatic renal cell carcinoma (mRCC) have been approved. It is assumed that one of the benefits is a delay in health-related quality of life (HRQoL) deterioration as a result of a delay in progression of disease. However, little data are available supporting this relationship. This study aims to provide insight into the most important determinants of HRQoL (including progression of disease) of patients with mRCC. Methods A patient registry (PERCEPTION) was created to evaluate treatment of patients with (m)RCC in the Netherlands. HRQoL was measured, using the EORTC QLQ-C30 and EQ-5D-5L, every 3 months in the first year of participation in the study, and every 6 months in the second year. Participation started as soon as possible following a diagnosis of (m)RCC. Random effects models were used to study associations between HRQoL and patient and disease characteristics, symptoms and treatment. Results Eighty-seven patients with mRCC completed 304 questionnaires. The average EORTC QLQ-C30 global health status was 69 (SD, 19) before progression and 61 (SD, 22) after progression of disease. Similarly, the average EQ-5D utility was 0.75 (SD, 0.19) before progression and 0.66 (SD, 0.30) after progression of disease. The presence of fatigue, pain, dyspnoea, and the application of radiotherapy were associated with significantly lower EQ-5D utilities. Conclusions Key drivers for reduced HRQoL in mRCC are disease symptoms. Since symptoms increase with progression of disease, targeted therapies that increase PFS are expected to postpone reductions in HRQoL in mRCC.

1 August 2018 in HemaSphere
Verified
Journal Article
Open access
SVSilvia G.R. Verelst
Silvia G.R. Verelst
HBHedwig M. Blommestein
Hedwig M. Blommestein
SGSaskia De Groot
Saskia De Groot
SGSebastian Gonzalez‐McQuire
Sebastian Gonzalez‐McQuire
LDLucy DeCosta
Lucy DeCosta
PSPieter Sonneveld
Pieter Sonneveld
Supplemental Digital Content is available in the text

1 April 2017 in Value in Health
Verified
Journal Article
Closed access
SGSaskia de Groot
Saskia de Groot
NLNaomi van der Linden
Naomi van der Linden
MFMargreet G. Franken
Margreet G. Franken
HBHedwig M. Blommestein
Hedwig M. Blommestein
BLBrenda Leeneman
Brenda Leeneman
CGCarin A. Uyl-De Groot
Carin A. Uyl-De Groot

1 September 2016 in Urology
Verified
Journal Article
Closed access
SGSaskia de Groot
Saskia de Groot
WRWilliam K. Redekop
William K. Redekop
SSStefan Sleijfer
Stefan Sleijfer
EOEgbert Oosterwijk
Egbert Oosterwijk
ABAxel Bex
Axel Bex
CGCarin A. Uyl-De Groot
Carin A. Uyl-De Groot

18 April 2015 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
HBHedwig M. Blommestein
Hedwig M. Blommestein
SVSilvia G. R. Verelst
Silvia G. R. Verelst
SGSaskia de Groot
Saskia de Groot
PHPeter C. Huijgens
Peter C. Huijgens
PSPieter Sonneveld
Pieter Sonneveld
CGCarin A. Uyl‐De Groot
Carin A. Uyl‐De Groot